CONOSCERE. PREVENIRE. ORIENTARSI.Un progetto informativo senza fini di lucro
INFORMAZIONE E CONSAPEVOLEZZA, INSIEME.

INFORMAZIONE E APPROFONDIMENTO

Females Display Greater Disease Severity in a Mouse Model of Vitiligo

Questo articolo proviene da Pigment Cell & Melanoma Research.

Il contenuto è riportato a solo scopo informativo e divulgativo: la proprietà e la responsabilità restano dell’autore e della fonte originale, e le informazioni non sostituiscono in alcun modo il parere del medico. Ringraziamo Pigment Cell & Melanoma Research per il prezioso lavoro di informazione: puoi leggere l’articolo originale sul loro sito.

This article comes from Pigment Cell & Melanoma Research.

The content is shared for informational and educational purposes only: ownership and responsibility remain with the original author and source, and this information is no substitute for medical advice. We thank Pigment Cell & Melanoma Research for their valuable work: you can read the original article on their website.

Pigment Cell &Melanoma Research, Volume 39, Issue 6, November 2026.

Pubblicato: 07/11/2026

Females Display Greater Disease Severity in a Mouse Model of Vitiligo

We compared depigmentation in vitiligo-prone, h3TA2 mice among males and females, and explored the effects of treatment with HSP70i

Q435A
plasmid DNA, delivered by biolistic administration. Mice shown from each cohort exemplify increased depigmentation among female mice and the treatment benefit of HSP70iQ435A.

ABSTRACT

Vitiligo is an autoimmune disease characterized by progressive depigmentation of the skin due to T cell-mediated destruction of melanocytes. Disease onset varies but usually initiates during adolescence. Sex differences in disease development and therapeutic outcomes have not been explored. We previously associated stress induced HSP70i with immune activation in depigmentation and showed that HSP70iQ435A can tolerize dendritic cells (DCs) to prevent cutaneous recruitment and activation of T cells. Among male and female vitiligo-prone mice, we investigated the long-term efficacy of HSP70iQ435A plasmid DNA treatment introduced by biolistic administration at varying stages of vitiligo development. Mice were followed up to 46 weeks of age. Female mice exhibited 1.89-fold greater depigmentation than males overall, while both responded proportionally to treatment with effects lasting throughout. This sex difference was associated with significantly elevated IFN-γ secretion by melanocyte-reactive T cells among female mice. Humoral responses to the protein remained readily detectable at end point regardless of treatment interval. These findings also suggest greater benefit from earlier intervention.

Leggi l'articolo originale su Pigment Cell & Melanoma Research

PUBBLICITÀ

Informazione, non una diagnosi.

Questi contenuti non sostituiscono una visita medica. Se noti un cambiamento o hai dubbi, rivolgiti al medico.

PUBBLICITÀ